Aptevo Therapeutics (APVO)
4.59
-0.13 (2.75%)
Upcoming Events
Latest Headlines
Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo
May 28, 2026 8:03 PM - SEC Filing
Aptevo Therapeutics names Mary Janatpour as chief scientific officer
May 28, 2026 8:05 AM - StreetInsider
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
May 28, 2026 8:05 AM - StreetInsider
Form 8-K Aptevo Therapeutics Inc. For: May 25
May 27, 2026 4:06 PM - SEC Filing
Aptevo and Niowave form partnership for cancer drug development
May 27, 2026 8:05 AM - StreetInsider
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
May 27, 2026 8:05 AM - StreetInsider
Form 10-Q Aptevo Therapeutics Inc. For: Mar 31
May 13, 2026 4:16 PM - SEC Filing
Form 8-K Aptevo Therapeutics Inc. For: May 13
May 13, 2026 4:06 PM - SEC Filing
Aptevo names Jeff Lamothe CEO, reports AML trial progress
May 13, 2026 8:07 AM - StreetInsider
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 13, 2026 8:07 AM - StreetInsider
Form 8-K Aptevo Therapeutics Inc. For: May 06
May 6, 2026 4:09 PM - SEC Filing
Aptevo reports 87% clinical benefit rate in frontline AML trial
May 6, 2026 8:10 AM - StreetInsider
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D
May 6, 2026 8:09 AM - StreetInsider
Form 10-K Aptevo Therapeutics Inc. For: Dec 31
March 26, 2026 4:17 PM - SEC Filing
Form 8-K Aptevo Therapeutics Inc. For: Mar 26
March 26, 2026 4:05 PM - SEC Filing
Aptevo Provides State of the Business Report and 2025 Financial Results
March 26, 2026 8:05 AM - StreetInsider
Aptevo to Participate in March 2026 Conferences
March 19, 2026 8:05 AM - StreetInsider
Full Article List
